Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Adegramotide/nelatimotide - Sumitomo Pharma

Next Previous
X
Search
Drug Profile

Adegramotide/nelatimotide - Sumitomo Pharma

Alternative Names: Adegramotide and nelatimotide; DSP 7888; Ombipepimut-S; WT1 cancer peptide vaccine - Sumitomo Pharma

Latest Information Update: 19 Jul 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sumitomo Dainippon Pharma
  • Developer Kyoto Prefectural University of Medicine; Osaka University; Sumitomo Pharma; Sumitomo Pharma America; Wakayama Medical University
  • Class Antineoplastics; Cancer vaccines; Immunotherapies; Peptide vaccines
  • Mechanism of Action T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myelodysplastic syndromes; Brain cancer
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Acute myeloid leukaemia; Glioblastoma; Glioma; Haematological malignancies; Myelodysplastic syndromes; Pancreatic cancer; Soft tissue sarcoma; Solid tumours

Most Recent Events

  • 02 Jun 2023 Updated efficacy and adverse events data from a phase III WIZARD201G trial in Glioblastoma presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)
  • 31 Jan 2023 Discontinued - Phase-I for Pancreatic cancer (Combination therapy, First-line therapy, Metastatic disease) in Japan (Intradermal) prior to January 2023
  • 31 Jan 2023 Discontinued - Phase-I for Solid tumours (Late-stage disease) in USA (Intradermal) prior to January 2023

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top